- Previous Close
274.00 - Open
275.00 - Bid 270.00 x --
- Ask 288.00 x --
- Day's Range
270.00 - 275.00 - 52 Week Range
140.05 - 339.00 - Volume
23,400 - Avg. Volume
14,744 - Market Cap (intraday)
3.105B - Beta (5Y Monthly) -0.10
- PE Ratio (TTM)
30.79 - EPS (TTM)
8.77 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Trident Lifeline Limited, a pharmaceutical company, engages in the manufacture and marketing of finished dosages in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. It offers pharmaceutical products in the form of tablets, capsules, liquid orals, external preparations, gel, mouthwash, and lotion; and nutraceutical tablets, capsules, liquids, sachets, oral sprays, and effervescent tablets, as well as ice gels, pastes, solutions, suspension, syrup, cream, drypowders, and toothpastes. The company has strategic alliance with National Institutes of Pharmaceutical Education and Research- Ahmedabad (NIPER-A) regarding the technology transfer of Vorinostat- one of the crucial medications for treating Cutaneous T-Cell Lymphoma (CTCL). The company was incorporated in 2014 and is based in Surat, India.
www.tridentlifeline.com40
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: TLL.BO
View MorePerformance Overview: TLL.BO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLL.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLL.BO
View MoreValuation Measures
Market Cap
3.15B
Enterprise Value
3.31B
Trailing P/E
31.22
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.27
Price/Book (mrq)
5.47
Enterprise Value/Revenue
5.53
Enterprise Value/EBITDA
19.49
Financial Highlights
Profitability and Income Statement
Profit Margin
16.87%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
598.82M
Net Income Avi to Common (ttm)
100.99M
Diluted EPS (ttm)
8.77
Balance Sheet and Cash Flow
Total Cash (mrq)
65.72M
Total Debt/Equity (mrq)
39.64%
Levered Free Cash Flow (ttm)
--